DocDollars

Sumitomo Pharma Co., Ltd.

Japan · Reporting entity ID 100000010437

Total reported 2019–2025
$17.3M
#354 of 2,960 reporting companies — 0% of all reported industry payments
$6.97M in general payments across 613 records, plus $10.3M in research funding across 50 records.

How it breaks down

General payments $6,971,209
Research funding $10,345,921

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Sumitomo Pharma Co., Ltd. reported $17.3M to US doctors and teaching hospitals from 2019 to 2025, ranking #354 of 2,960 reporting companies. 60% of that was research funding and 40% general payments such as consulting, speaking, food and travel. 613 general payment records and 50 research records were filed.

Common questions about Sumitomo Pharma Co., Ltd.

How much has Sumitomo Pharma Co., Ltd. paid US doctors?

Sumitomo Pharma Co., Ltd. reported $17,317,130 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $6,971,209 in general payments, $10,345,921 in research funding.

How does Sumitomo Pharma Co., Ltd. rank among drug and device companies?

It ranks #354 of 2,960 reporting entities by total reported value, about 0% of all industry payments in the dataset.

Does a payment from Sumitomo Pharma Co., Ltd. mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.